You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Guidance on product changes in ELF3
|Version||Description of change||Author||Effective date|
|V1.1||Added new changes to clarify rules for amendments to MDD / MSD for restricted ingredients; and changes to indications / MDD or MSD occurring simultaneously with a product name change||OCM||30/07/2012|
The Changes Tables included in this document should not be considered an exhaustive list and will be updated by the TGA from time to time.
The tables refer to changes using the same terminology that is designated in the ELF 3 system. For further information on the types of changes detailed, sponsors should make reference to the terms defined in Section 9.5 – Terminology Used to Describe the Changes of the Australian Regulatory Guidelines (ARCGM) Part II – Listed Complementary Medicines.
This document supersedes the September 2004 changes document.